Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas

Journal of Neuro-Oncology

Volumn 38, Issue 1, 1998, Pages 41-49

  Ohkoudo, Mitsuaki ^a   Sawa, Hiroki ^a   Hara, Mitsuhiro ^a   Saruta, Kazuhiko ^a   Aiso, Toshiko ^a   Ohki, Reiko ^a   Yamamoto, Hiroshi ^a   Maemura, Eiji ^b   Shiina, Yoshio ^a   Fujii, Masahiko ^a   Saito, Isamu ^a  

^a KYORIN UNIVERSITY   (Japan)

^b Akiru Municipal General Hospital   (Japan)

Author keywords

Immunohistochemistry; Ki 67; MDM2; Meningiomas; p53; PCR SSCP method; Recurrence

Indexed keywords

KI 67 ANTIGEN; PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MENINGIOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR GROWTH;

ADULT; AGED; ANTIGENS, NUCLEAR; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 6844260556     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005946001915     Document Type: Article

References (33)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991
2. Marx J: How p53 suppresses cell growth. Science 262: 1644-1645, 1993
3. Chang F, Syrjänen S, Tervahauta A, Syrjänen K: Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer 68: 653-661, 1993
4. Ellison DW, Gatter KC, Steart PV, Lane DP, Weller RO: Expression of the p53 protein in a spectrum of astrocytic tumours. J Pathol 168: 383-386, 1992
5. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson ADJ: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66: 373-385, 1992
6. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M, Petersen I, Höll T, Wiestler OD, Kleihues P: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 8: 74-80, 1993
7. Oliner JD, Kinzler KW, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992
9. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993
10. Wu X, Bayle JH, Olson D, Levine AJ: The p53-MDM-2 autoregulatory feedback loop. Genes Dev 7: 1126-1132, 1993
11. Zauberman A, Barak Y, Ragimov N, Levy N, Oren M: Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J 12: 2799-2808, 1993
12. Leach FS, Tokino T, Maltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234, 1993
13. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736-2739, 1993
14. Goelz SE, Hamilton SR, Vogelstein B Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 130: 118-126, 1985
15. Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J: Analysis of p53 gene mutations in low- and high-grade astrocytomas by polymerase chain reaction-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87:225-232, 1994
16. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989
17. Christensen D, Laursen H, Klinken L: Prediction of recurrence in meningiomas after surgical treatment. A quantitative approach. Acta Neuropathol (Berl) 61: 130-134, 1983
18. Matsuno A, Fujimaki T, Sasaki T, Nagashima T, Ide T, Asai A, Matsuura R, Utsunomiya H, Kirino T: Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 91: 504-510, 1996
19. Adegbite AB, Khan MI, Paine KW, Tan LK:The recurrence of intracranial meningiomas after surgical treatment. J Neurosurg 58: 51-56, 1983
20. Paulus W, Meixensbergers J, Hofmann E, Roggendorf W: Effect of embolisation of meningioma on Ki-67 proliferation index. J Clin Pathol 46: 867-877, 1993
21. Ohta M, Iwaki T, Kitamoto T, Takeshita I, Tateishi J, Fukui M: MIB-1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Cancer 74: 3176-3189, 1994
22. Lindblom A, Ruttledge M, Collins VP, Nordenskjöld M, Dumanski JP: Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 56: 354-357, 1994
23. Karamitopoulou E, Perentes E, Diamantis I: p53 protein expression in central nervous system tumours: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 85: 611-616, 1993
24. Ellison DW, Lunec J, Gallagher PJ, Steart PV, Jaros E, Gatter KC: Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol 21: 136-142, 1995
25. Wang JL, Zhang ZJ, Hartman M, Smits A, Westermark B, Muhr C, Nister M: Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int J Cancer 64: 223-228, 1995
26. Albrecht S, Gooodman JC, Rajagopolan S, Levy M, Cech DA, Cooley LD: Malignant meningioma in Gorlin's syndrome: cytogenetic and p53 gene analysis. J Neurosurg 81: 466-471, 1994
27. Chozick BS, Benzil DL, Stopa EG, Pezzullo JC, Knuckey NW, Epstein MH, Finkelstein SD, Finch PW: Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J Neurooncol 27: 117-126, 1996
28. Hall PA, Lane DP: p53 in tumour pathology: can we trust immunohistochemistry? Revisited! J Pathol 172: 1-4, 1994
29. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992
30. Girod SC, Cesarz D, Fischer U, Krueger GR: Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res 15: 1453-1458, 1995
31. Martinez JC, Mateo M, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Garcia P, Lopez C, Martinez P, Piris MA: MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue. Comparative study with p53 expression. J Pathol 177: 27-34, 1995
32. Barak Y, Juven T, Haffner R, Oren M: MDM-2 expression is induced by wild type p53 activity. EMBO J 2:461-468, 1993
33. Chen J, Marechal V, Levine A Jr: Mapping of the p53 and MDM2 interaction domains. Mol Cell Biol 13: 4107-4114, 1993